Selecting Patients for Exclusive Permanent Implant Prostate Brachytherapy: The Experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital Group on 809 Patients

Results of a cohort of 200 hormone-naïve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team

“…Our results echo those of the literature [15][16][17][18][19], but our process comprises some specificities: Table 3 Acute toxicity after brachytherapy for prostate cancer according to Common terminology criteria for adverse events (CTC AE) v2.0 (n = 190). Toxicité aiguë après curiethérapie pour un cancer de la prostate selon l'échelle CTC AE v2.0 (n = 190).…”

“…A pelvic CT scan was done 1 month after brachytherapy to check the number of seeds and the dosimetry. The median number of PSA assessment per patient was 12 [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. No chest X-ray was done to assess the pulmonary migration of permanent interstitial sources.…”

Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003

“…This selection was based on the criteria set by the French urology association (AFU) and the French society of radiation oncology (SFRO) [8]. This select group intermediate-risk patients would now belong to the "favourable-intermediate" subgroup [8].…”

“…The pathology slides could therefore not be systematically obtained from the referring institutions for review. Of note, in recent years, only patients with Gleason 7 (3 + 4) are considered suitable for prostate brachytherapy by our group [8].…”

“…With excellent results reported by both single and multiinstitutional studies, low-dose rate permanent implant prostate cancer brachytherapy is now widely considered as a wellrecognized exclusive treatment for low-risk, and increasingly for intermediate-risk localized prostate cancer [1][2][3][4][5][6][7][8][9][10].…”